ORIC Pharmaceuticals (ORIC)
Biotech
Close on Oct 26, 2026 (from our latest article): $8.96
- Market value
- $929Mat the Oct 26 close
- Cash used, 12 months
- $112M12 months to Jun 30, 2026 (10-Q)
- Net cash
- $388Mat Jun 30, 2026
- Worst fall since listing
- −93.9%Dec 24, 2020 to Nov 7, 2022; not back to that high (−80.7% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
ORIC licensed both of its current drugs in 2020 and has funded their development through private placements, a direct stock sale to Pfizer and at-the-market share offerings; since 2022 its share count, including pre-funded warrants (rights bought upfront that need only $0.0001 a share to exercise), nearly tripled.
▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash
Updated Oct 27, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for ORIC Pharmaceuticals, FY2018–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Free cash flow was positive in 0 of the 8 years shown; FY2025: −$112M.
Margins
Margins are not charted: fewer than two years with revenue and operating income.
Diluted share count
The diluted share count rose 131% from FY2021 to FY2025, to 88M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | −$129M | −$111M | $0.7M | −$112M |
| FY2024 | — | — | — | −$128M | −$113M | $1M | −$114M |
| FY2023 | — | — | — | −$101M | −$86M | $0.8M | −$87M |
| FY2022 | — | — | — | −$89M | −$75M | $2M | −$77M |
| FY2021 | — | — | — | −$79M | −$60M | $0.9M | −$60M |
| FY2020 | — | — | — | −$74M | −$45M | $0.7M | −$46M |
| FY2019 | — | — | — | −$27M | −$24M | $0.8M | −$24M |
| FY2018 | — | — | — | −$21M | −$21M | $0.5M | −$21M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 88M | $392M | — | $25M | — | — |
| FY2024 | 70M | $256M | — | $20M | — | — |
| FY2023 | 51M | $235M | — | $15M | — | — |
| FY2022 | 40M | $228M | — | $14M | — | — |
| FY2021 | 38M | $280M | $11M | $13M | — | — |
| FY2020 | — | $294M | — | $5M | — | — |
| FY2019 | — | $89M | — | $1M | — | — |
| FY2018 | — | $43M | — | $0.5M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Oct 30, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Cash for FY2018 includes restricted cash (the only cash total tagged).
Returns by year
| Year | ORIC | S&P 500 |
|---|---|---|
| 2019 | — | +31.5% |
| 2020 | +31.4%† | +18.4% |
| 2021 | −56.6% | +28.7% |
| 2022 | −59.9% | −18.1% |
| 2023 | +56.2% | +26.3% |
| 2024 | −12.3% | +25.0% |
| 2025 | +1.4% | +17.9% |
| 2026 to date | −5.9% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (Apr 24, 2020); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- IMCR Immunocore Up 9.1%
- AGIO Agios Down 9.9%
- NRIX Nurix Therapeutics Down 38.2%
- VERA Vera Down 1.2%
- XNCR Xencor Up 15.9%
- VKTX Viking Therapeutics
Show all 17
- SLS SELLAS Up 156.4%
- TNGX Tango Therapeutics Down 16.4%
- IOVA Iovance Down 35.4%
- ARWR Arrowhead Down 15.3%
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- ALNY Alnylam
- GMAB Genmab Up 28.3%
- MRNA Moderna Down 17.6%
Questions about ORIC Pharmaceuticals
- Why did ORIC Pharmaceuticals stock fall on Oct 26, 2026?
- ORIC shares fell about 32% on Monday after Johnson & Johnson reported early results over the weekend for JNJ-6143, an experimental pill for the same advanced prostate cancer that ORIC's lead drug rinzimetostat targets. TIKR linked the decline to competitive concerns, citing Leerink analyst Asthika Goonewardene's view that JNJ-6143 poses a greater potential threat to rinzimetostat. The two drugs have not been compared directly in a clinical trial. Read the article →
- Does ORIC Pharmaceuticals need to raise money?
- At its past rate of cash use, its cash would run below zero around Q4 2029; the company says: into H2 2028. Companies usually raise money well before that. Read the Long View →
- How fast is ORIC Pharmaceuticals's share count growing?
- Common shares plus pre-funded warrants rose 174% from Dec 31, 2021 to Jun 30, 2026, about 25.1% a year compounded. Read the Long View →